DRIO PE Ratio & Valuation,Is DRIO Overvalued

DRIO Relative Valuation

DRIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, DRIO is overvalued; if below, it's undervalued.

Historical Valuation

DarioHealth Corp (DRIO) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.79 is considered Undervalued compared with the five-year average of -2.14. The fair price of DarioHealth Corp (DRIO) is between 23.90 to 52.12 according to relative valuation methord. Compared to the current price of 12.90 USD , DarioHealth Corp is Undervalued By 46.03%.

Relative Value

Fair Zone

23.90-52.12

Current Price：12.90

46.03%

Undervalued

-0.79

-3.67

EV/EBITDA

DarioHealth Corp. (DRIO) has a current EV/EBITDA of -3.67. The 5-year average EV/EBITDA is -3.06. The thresholds are as follows: Strongly Undervalued below -6.33, Undervalued between -6.33 and -4.69, Fairly Valued between -1.42 and -4.69, Overvalued between -1.42 and 0.21, and Strongly Overvalued above 0.21. The current Forward EV/EBITDA of -3.67 falls within the Historic Trend Line -Fairly Valued range.

-2.62

EV/EBIT

DarioHealth Corp. (DRIO) has a current EV/EBIT of -2.62. The 5-year average EV/EBIT is -1.77. The thresholds are as follows: Strongly Undervalued below -4.29, Undervalued between -4.29 and -3.03, Fairly Valued between -0.50 and -3.03, Overvalued between -0.50 and 0.76, and Strongly Overvalued above 0.76. The current Forward EV/EBIT of -2.62 falls within the Historic Trend Line -Fairly Valued range.

2.79

DarioHealth Corp. (DRIO) has a current PS of 2.79. The 5-year average PS is 4.19. The thresholds are as follows: Strongly Undervalued below -3.45, Undervalued between -3.45 and 0.37, Fairly Valued between 8.00 and 0.37, Overvalued between 8.00 and 11.82, and Strongly Overvalued above 11.82. The current Forward PS of 2.79 falls within the Historic Trend Line -Fairly Valued range.

-3.05

P/OCF

DarioHealth Corp. (DRIO) has a current P/OCF of -3.05. The 5-year average P/OCF is -3.68. The thresholds are as follows: Strongly Undervalued below -8.61, Undervalued between -8.61 and -6.14, Fairly Valued between -1.21 and -6.14, Overvalued between -1.21 and 1.26, and Strongly Overvalued above 1.26. The current Forward P/OCF of -3.05 falls within the Historic Trend Line -Fairly Valued range.

-1.28

P/FCF

DarioHealth Corp. (DRIO) has a current P/FCF of -1.28. The 5-year average P/FCF is -3.20. The thresholds are as follows: Strongly Undervalued below -7.50, Undervalued between -7.50 and -5.35, Fairly Valued between -1.05 and -5.35, Overvalued between -1.05 and 1.10, and Strongly Overvalued above 1.10. The current Forward P/FCF of -1.28 falls within the Historic Trend Line -Fairly Valued range.

DarioHealth Corp (DRIO) has a current Price-to-Book (P/B) ratio of 0.95. Compared to its 3-year average P/B ratio of 0.79 , the current P/B ratio is approximately 20.25% higher. Relative to its 5-year average P/B ratio of 1.39, the current P/B ratio is about -31.83% higher. DarioHealth Corp (DRIO) has a Forward Free Cash Flow (FCF) yield of approximately -37.87%. Compared to its 3-year average FCF yield of -85.96%, the current FCF yield is approximately -55.95% lower. Relative to its 5-year average FCF yield of -62.91% , the current FCF yield is about -39.81% lower.

0.95

P/B

Median3y

0.79

Median5y

1.39

-37.87

FCF Yield

Median3y

-85.96

Median5y

-62.91

Competitors Valuation Multiple

The average P/S ratio for DRIO's competitors is 21.21, providing a benchmark for relative valuation. DarioHealth Corp Corp (DRIO) exhibits a P/S ratio of 2.79, which is -86.84% above the industry average. Given its robust revenue growth of -32.55%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of DRIO decreased by 2.18% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -166.11 to -209.03.

The secondary factor is the P/E Change, contributed 4.53%to the performance.

Overall, the performance of DRIO in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-32.55%

7.42M → 5.01M

Revenue Growth

25.84%

-166.11 → -209.03

Margin Expansion

4.53%

-0.89 → -0.93

P/E Change

-2.18%

12.40 → 12.13

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is DarioHealth Corp (DRIO) currently overvalued or undervalued?

What is DarioHealth Corp (DRIO) fair value?

DRIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of DarioHealth Corp (DRIO) is between 23.90 to 52.12 according to relative valuation methord.

How does DRIO's valuation metrics compare to the industry average?

What is the current P/B ratio for DarioHealth Corp (DRIO) as of Jan 08 2026?

As of Jan 08 2026, DarioHealth Corp (DRIO) has a P/B ratio of 0.95. This indicates that the market values DRIO at 0.95 times its book value.

What is the current FCF Yield for DarioHealth Corp (DRIO) as of Jan 08 2026?

As of Jan 08 2026, DarioHealth Corp (DRIO) has a FCF Yield of -37.87%. This means that for every dollar of DarioHealth Corp’s market capitalization, the company generates -37.87 cents in free cash flow.

What is the current Forward P/E ratio for DarioHealth Corp (DRIO) as of Jan 08 2026?

As of Jan 08 2026, DarioHealth Corp (DRIO) has a Forward P/E ratio of -0.79. This means the market is willing to pay $-0.79 for every dollar of DarioHealth Corp’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for DarioHealth Corp (DRIO) as of Jan 08 2026?

As of Jan 08 2026, DarioHealth Corp (DRIO) has a Forward P/S ratio of 2.79. This means the market is valuing DRIO at $2.79 for every dollar of expected revenue over the next 12 months.

DRIO Valuation